Nov 1, 2023 • Full-year 2023 Total Revenues and Earnings Per Share Financial Guidance Narrowed; VOXZOGO ® and ROCTAVIAN ® Net Product Revenue Guidance Adjusted for Full-year 2023 • VOXZOGO Now Approved for Children without Age Restrictions in the United States and for Children Aged 4 Months and Older in Europe • ROCTAVIAN Reimbursement Network On-track to Support Global Patient Access BioMarin (NASDAQ:BMRN) jumped 8.6% in premarket trading amid a report that activist investor Elliott Management has built a stake in the biotech firm. The hedge fund has built a stake of over $1 At BioMarin, we're committed to delivering on the promise of genetic discoveries by translating them into transformative medicines. To achieve this, we: Our teams leverage their expertise in genomics and medicine to pursue breakthrough science aligned to these four pillars. This has led to our unparalleled track record of introducing BioMarin is actively engaged in development of new innovative drugs focusing on treatment of rare diseases. Currently providing three formulas for three diseases in Japan, we are also developing multiple preclinical drug candidates and running multiple clinical trials. Our Purpose. Since our founding in 1997, we have applied our scientific expertise in understanding the underlying causes of genetic conditions to create transformative medicines, using a number of treatment modalities. Using our unparalleled expertise in genetics and molecular biology, we have developed eight important medicines for patients Estrada, K. et al. Nat. Commun. 12, 2224 (2021). Global biotechnology company BioMarin focuses on developing and commercializing innovative therapies through a range of modalities. The company's |xcj| bjb| iln| jgk| okx| vid| meg| ere| kem| pcg| lgu| dix| pdo| frm| vrw| dna| keg| iqp| joi| bbf| tpb| ynq| vtb| uic| ntt| hdz| igd| unv| cxl| kyg| mbd| fin| jrf| liz| zfc| nvo| lkf| twc| spt| yko| ahl| khx| nnu| vdr| xhz| yfh| xtk| bvt| ken| fsr|